Proteolysis targeted chimera (Protein Degrader) is a rapidly developed technology in recent years, which provides the possibility for many undruggable targets, and has become the focus of protein drug researchers. Hematologic malignanciesRead More…
In recent years, targeted protein degradation chimera (Protein Degrader) as a novel way to induce protein degradation has become a new drug discovery strategy. Compared with traditional protein inhibitor drugs, it hasRead More…
Protein Degraders is a novel technique in protein drug research field. Unlike traditional protein inhibitors, Protein Degraders are potential to target undruggable protein. Therefore, it has become a potential cancer therapy strategy.Read More…
Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family, which responds to a variety of cytokines, growth factors and other signals and activates the expression ofRead More…
Among the drugs developed in Arvinas, ARV-110 is the first oral PRAOTC small molecule drug to enter clinical trials in the field of proteolytic targeted chimerism, selectively targeting the degradation of androgenRead More…